Rein Therapeutics, Inc.

Analysis for Ticker: RNTX

Rein Therapeutics Inc is a company that claims to develop medicine for rare lung diseases like fibrosis, but its real business is a mathematical machine designed to feed lenders while original shareholders are left with nothing. The company is in a terminal crisis, begging the public to buy 30 million new shares for about 1,66$ each just to pay back predatory loans that are coming due in 06/2026. The math for a child is simple: you are asked to pay 1,66$ for a piece of paper that is actually worth less than zero because the company has a negative 0,11$ book value. Even after giving them money, the value of that share instantly drops to just 0,65$, which means a loss of 1,01$ the very second it is bought. With an accumulated deficit of over 401,0$ million and auditors who officially doubt the company can even stay open, the business is a burning building where the exits are blocked by debt.